Immunogenicity and safety of measles-mumps-rubella-varicella vaccine: A systematic review

Chinese Journal of Evidence-Based Medicine

Volumn 10, Issue 7, 2010, Pages 862-868

  Wu, Yan Mei ^a   Li, Ge ^a   Zhao, Wen Long ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Combined vaccine; Immunization safety; Immunogencity; System evaluation

Indexed keywords

MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; RUBELLA ANTIBODY;

ANTIBODY BLOOD LEVEL; BIOSIS; CHILD; COCHRANE LIBRARY; DRUG SAFETY; EVALUATION; FEVER; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE RASH; MEDLINE; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

EID: 77957745330     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. PAHO. WHO position on use of measles, mumps and rubella (MMR). Vaccine. EPI News letter, 2001, 23: 510
2. Centers for Disease Control and Prevention. Measles, mumps and rubella vaccine use and strategies for elimination of measles, rubella and congenital rubella syndrome and control of mumps recommendations of the Advisory Committee on Immunization Practice (ACIP). MMVR Morb Mortal Wkly Rep. 47 (NO.RR-8), 1998: 1-58.
3. Nation Health and Medical Research Council: The Australian immunization handbook. 7th ed. Canberra: Australian Government Publishing Service, 2002
4. Bartlett MJ, Burgess MA, McIntyre PB, et al. Parent and general practitioner preferences for infant immunization: reactogenicity or multiple injection. Aust Fam Physician, 1999, 28(1): S22-27.
5. Edwards KM, Decker MD. Combination vaccine: hopes and challenges. The Pediatric Infectious Disease Journal, 1994, 13: 345-347.
6. Nolan T, McIntyre P, Roberton D, et al. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubellavaricella (MMRV) vaccine. Vaccine, 2002, 21: 281-289. (Pubitemid 35346822)
7. Shinefield H, Black S, Digilio L, et al. Evaluation of a Quadrivalent, Measles, Mumps, Rubella and Varicella Vaccine in Healthy Children. The Pediatric Infectious Disease Journal, 2005, 24: 665-669. (Pubitemid 41140946)
8. Jay M, Wendy R, Jacqueline M, et al. The safety and immunogenicity of a Quadrivalent Measles, Mumps, Rubella and Varicella Vaccine in Healthy Children. The Pediatric Infectious Disease Journal, 2006, 25(7): 615-621.
9. Goh P, Lim FS, Han HH, et al. Safety and immunogenicity of Early Vaccination with Two Dose of Tetravalent Measles-Mumps-Rubella-Varicella(MMRV) Vaccine in Healthy Children from 9 months of age. Infection, 2007, (5): 326-333. (Pubitemid 47502355)
10. Schuster V, Otto W, Maurer L, et al. Immunogenicity and Safety Assessments After One and Two Doses of a Refrigerator-Stable Tetravalent Measles-Mumps-Rubella-Varicella Vaccine in Health Children During the Second Year of Life. The Pediatric Infectious Disease Journal, 2008, 27(8): 724-730.
11. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet, 1986, 1: 939-942.
12. Chen RT, Moses JM, Markowitz LE, et al. Adverse events following measles-mumps-rubella and measles vaccination in college students. Vaccine, 1991, (9): 297-299.
13. Centers for Disease Control and Prevention Measles. In: Atkinson W, Hamborsky J, Mclntyre L, Wolfe S (eds) Epidemiology and prevention of vaccine -preventable diseases (9th edn) Public Health Foundation, Washing DC 2006, 125-144.